

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignin 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/083,913	10/083,913 02/27/2002		Andrew Stoll	2002082-0002	6358
24280	7590	09/11/2003			
Choate, Ha		art e	EXAMINER		
Exchange Place 53 State Street				SPIVACK, PI	HYLLIS G
Boston, MA	Boston, MA 02109			ART UNIT	PAPER NUMBER
				1614	
				DATE MAILED: 09/11/2003	5

Please find below and/or attached an Office communication concerning this application or proceeding.

PTO-90C (Rev. 07-01)



## Application No.

10/083,913

Applicant(s)

Stoll

Office Action Summary Examiner

Phyllis G. Spivack

Art Unit **1614** 



The MAILING DATE of this communication a	ppears on the cover sheet with the correspondence address
Period for Reply	IC SET TO EVAIDE 1 MAONITH(S) EDOM
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.	IS SET TO EXPIRE MONTH(S) FROM
	36 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the
mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a repl	y within the statutory minimum of thirty (30) days will be considered timely.
	will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Any reply received by the Office later than three months after the mailing	• • • • • • • • • • • • • • • • • • • •
earned patent term adjustment. See 37 CFR 1.704(b).  Status	
1) Responsive to communication(s) filed on	·
2a) ☐ This action is <b>FINAL</b> . 2b) ☒ T	his action is non-final.
, ,	vance except for formal matters, prosecution as to the merits is r Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.
Disposition of Claims	
4) 💢 Claim(s) <u>1-27</u>	is/are pending in the application.
4a) Of the above, claim(s)	is/are withdrawn from consideration.
5)  Claim(s)	is/are allowed.
6)	is/are rejected.
7)	is/are objected to.
8) 💢 Claims <u>1-27</u>	are subject to restriction and/or election requirement.
Application Papers	
9) $\square$ The specification is objected to by the Exam	iner.
10) The drawing(s) filed on	is/are a) $\square$ accepted or b) $\square$ objected to by the Examiner.
Applicant may not request that any objection	to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
11) $\square$ The proposed drawing correction filed on	is: a) $\square$ approved b) $\square$ disapproved by the Examiner.
If approved, corrected drawings are required in	n reply to this Office action.
12) $\square$ The oath or declaration is objected to by the	Examiner.
Priority under 35 U.S.C. §§ 119 and 120	
13) Acknowledgement is made of a claim for for	reign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) $\square$ All b) $\square$ Some* c) $\square$ None of:	
1. $\square$ Certified copies of the priority document	nts have been received.
2. $\square$ Certified copies of the priority document	nts have been received in Application No
application from the Internation	
*See the attached detailed Office action for a lis	·
14) Acknowledgement is made of a claim for do	
a) U The translation of the foreign language pro	
_	mestic priority under 35 U.S.C. §§ 120 and/or 121.
Attachment(s)	4) []
1) Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).  5) Notice of Informal Patent Application (PTO-152)
2) Information Disclosure Statement(s) (PTO-1449) Paper No(s).  3) Information Disclosure Statement(s) (PTO-1449) Paper No(s).	6) Other:
Janoniation Disclosure Statement(s) (1 10-1445) raper 140(s).	0, 0.1.01.

Application/Control Number: 10/083913

Art Unit: 1614

## Election/Restriction

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-9, 21 and 22, drawn to methods of treating unipolar major depression comprising administering an omega-3 fatty acid, and a kit comprising an omega-3 fatty acid with a psychotropic medication, classified in class 514, subclass 558.
- II. Claims 10-20 and 23-27, drawn to an omega-3 phosphatidylcholine consisting of glycerol, wherein the α and β carbons of said glycerol are both esterified to a fatty acid, at least one of which is an omega-3 fatty acid, and the γ carbon of said glycerol is esterified to phosphocholine, pharmaceutical compositions thereof and a kit comprising an omega-3 phosphatidyl-choline with a psychotropic medication, classified in various subclasses of class 554.

The inventions are distinct, each from the other, for the following reasons:

The Groups have acquired a separate staus in the art as shown by their different classification and their recognized, divergent subject matter. The searches required for each Group are not co-extensive. Each Group is capable of supporting a separate patent. Thus restriction for examination purposes, as indicated, is proper.

Further, claims 21-27 are generic to a plurality of disclosed patentably distinct species comprising a psychotropic agent, as disclosed in the subject specification. Applicant is required

Application/Control Number: 10/083913

Page 3

Art Unit: 1614

under 35 U.S.C. 121 to elect a single disclosed species of a psychotropic agent, even though this

requirement is traversed.

Should Applicant traverse on the ground that the species are not patentably distinct,

Applicant should submit evidence or identify such evidence now of record showing the species to

be obvious variants or clearly admit on the record that this is the case. In either instance, if the

Examiner finds one of the inventions unpatentable over the prior art, the evidence or admission

may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is advised that to be complete, the reply to this requirement must include an

election of the invention to be examined even though the requirement is traversed (37 CFR

1.143).

Any inquiry concerning this communication should be directed to Phyllis Spivack at

telephone number 703-308-4703.

September 9, 2003

PHYLLIS SPIVACK PRIMARY EXAMINED

Phyllis Spivack